Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

What is Bristol-Myers Squibb Company?

Bristol Myers Squibb (BMY) is a pharmaceutical company known for its innovative treatments in various therapeutic areas. The overall market for pharmaceuticals has been volatile, with companies facing challenges such as declining revenues and legal issues.

Why is Bristol-Myers Squibb Company going up?

BMY stock is up 5.1% on Feb 6, 2026 16:02

• Despite industry challenges, Bristol Myers Squibb (BMY) saw a strong bullish movement in its stock price.
• Investor optimism towards BMY is likely driven by the company surpassing analysts' expectations for adjusted earnings and revenue in the fourth quarter.
• The positive sentiment towards BMY could also be linked to the upcoming conference call to discuss financial results, hinting at potential positive developments or strategic plans.
• This upward trend may indicate that investors are focusing on Bristol Myers Squibb's resilience and ability to navigate industry challenges, rather than broader market uncertainties impacting other pharmaceutical companies.

BMY Price Chart

BMY Technical Analysis

BMY News

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles and It Sees Continued Declines

Biogen's stock rose despite declining sales and poor performance across most of its drug portfolio in the fourth quarter. The company still managed to beat analysts' expectations for adjusted earnings and revenue. Investors appears to be looking past the recent declines.

https://www.barrons.com/articles/biogen-earnings-stock-price-multiple-sclerosis-97907d44?gaa_at=eafs&gaa_n=AWEtsqdxu2zjP-eXs9_tFGEwWV1L_zmhdWX6oj1CVcZzCpnDPHT_yqPhdCOV&gaa_ts=6985ef0f&gaa_sig=m3cG-Xuf-rPeJc2DnETcNcmLfUviJJ1aJaV7W3EvS93Y61Bf1LsWLE_Dc5KCoJC-YmNbFSeDUiPro1qyAxonww%3D%3D

Incyte’s Zynyz Wins CHMP Backing And Opens New EU Opportunity

Incyte's Zynyz (retifanlimab) has received a positive opinion from the CHMP of the EMA for the first-line treatment of metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal. This recommendation is a significant step towards European approval and market entry, leveraging Phase 3 data showing improved progression-free survival. The approval would diversify Incyte's oncology portfolio, providing a new revenue stream in a rare cancer indication alongside its existing focus on immuno-oncology.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-incy/incyte/news/incytes-zynyz-wins-chmp-backing-and-opens-new-eu-opportunity

Blue Owl Capital Faces Legal Woes Amid Falling Stock Prices

Blue Owl Capital is facing legal challenges from Rosen Law Firm and Faruqi & Faruqi due to alleged undisclosed liquidity difficulties, causing investor losses and a significant stock dip. Amid these lawsuits and market concerns, UBS forecasts the company to underperform, particularly due to its heavy involvement in direct lending. The company's financial overview reveals high revenue but also a high PE ratio and substantial long-term debt, painting a worrying picture of liquidity mismanagement.

https://stockstotrade.com/news/blue-owl-capital-inc-owl-news-2026_02_05/

Pharmaceutical giant to close 20,000-square-foot facility, lay off 20

Charles River Laboratories is closing its 20,000-square-foot cell therapy facility in Hanover, Maryland, resulting in 20 layoffs. This closure is part of a trend of biotech companies shutting down operations in the region. The facility specialized in gene-edited cell therapies.

https://www.bizjournals.com/baltimore/news/2026/02/05/charles-river-labs-hanover-closure-layoff-biotech.html

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

Bristol Myers Squibb (NYSE: BMY) has released its financial results for the fourth quarter and full-year 2025. The company announced that detailed financial information, including the earnings press release and investor presentation, is available on its Investor Relations website. A conference call and live audio webcast for analysts and investors was scheduled for February 5, 2026, at 8:00 a.m. ET to review these results.

https://www.biospace.com/press-releases/bristol-myers-squibb-reports-fourth-quarter-and-full-year-financial-results-for-2025

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 6.9% Today

Ethereum ($ETH) Crypto Forecast: Down 6.4% Today

Bristol-Myers Squibb Company Price History

01.09.2025 - BMY Stock was up 5.5%

• The bullish movement in BMY could be attributed to investors favoring its growth potential despite facing generic headwinds.
• The comparison with Merck (MRK) might have highlighted BMY's resilience and potential for future success, leading to increased investor confidence.
• The market's positive response indicates that BMY's strategic initiatives and focus on new treatments are resonating well with investors, driving the stock price higher.

05.01.2026 - BMY Stock was up 5.7%

• Bristol Myers Squibb's stock surged due to its fourth-quarter earnings surpassing analyst expectations, showcasing a strong financial performance.
• Investor excitement was further boosted by the positive outlook provided by the company, reflecting confidence in its future growth prospects.
• Revenue growth, particularly driven by successful immuno-oncology treatments, helped offset the decline in sales of older drugs, contributing to overall positive market sentiment.
• The impressive performance in Q4 2025 and the promising outlook for 2026 underscored Bristol Myers Squibb's resilience in adapting to market changes and solidifying its position in the pharmaceutical industry.

05.01.2026 - BMY Stock was up 3.2%

• Despite disappointments with Eliquis and Cobenfy, Bristol Myers Squibb's strong fourth-quarter earnings report and revenue beat have propelled its stock to a bullish movement.
• The company's focus on its Growth Portfolio, featuring drugs like Opdivo and Reblozyl, has driven significant revenue growth and instilled confidence in investors.
• Bristol Myers Squibb's strategic approach to leaning on new products and potential M&A opportunities to expand its therapeutic areas has resonated well with the market, leading to the positive market movement.
• The company's ability to exceed analyst expectations and provide an optimistic outlook for future revenues has further fueled investor excitement and contributed to the bullish trend in its stock price.

03.11.2025 - BMY Stock was up 5.5%

• Bristol Myers Squibb's stock surged by approximately 6% after announcing a delay in the readout of a crucial Phase 3 clinical trial for its drug Cobenfy, designed for Alzheimer's disease psychosis. The market reacted positively to this unexpected news, indicating investor optimism about the drug's potential success.
• The decision to enroll more patients in the clinical trial demonstrates the company's commitment to ensuring data integrity and addressing unmet medical needs in Alzheimer's disease, further boosting investor confidence in Bristol Myers Squibb.
• Additionally, the successful achievement of a drug discovery milestone in collaboration with Terray Therapeutics showcases Bristol Myers Squibb's dedication to leveraging innovative technologies like AI to accelerate drug discovery processes, potentially leading to the development of novel and effective treatments.
• The continuation of the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer's Disease, despite site irregularities, underlines Bristol Myers Squibb's adherence to rigorous clinical standards and its proactive approach to resolving challenges in clinical trials, reinforcing investor trust in the company's research and development efforts.

03.11.2025 - BMY Stock was up 5.1%

• BMY's stock surged after a positive update on its late-stage clinical trial for treating psychosis associated with Alzheimer’s disease, signaling progress in its research endeavors.
• A collaboration milestone with Terray Therapeutics highlights BMY's utilization of AI-enabled drug discovery technologies to accelerate small molecule drug development, potentially enhancing investor confidence.
• Despite delays in the Adept-2 study for Cobenfy in Alzheimer's psychosis, efforts to rectify site irregularities and continue enrolling new patients demonstrate BMY's commitment to upholding clinical standards and addressing medical needs, possibly contributing to the stock's bullish performance.

05.00.2026 - BMY Stock was down 1.7%

• Increased investments by Railway Pension Investments Ltd and CWA Asset Management Group LLC in Bristol Myers Squibb (BMY) may have hinted at uncertainties about the company's future performance, influencing the bearish trajectory.
• While Bristol Myers Squibb exceeded Q3 earnings and revenue projections and raised its dividend, market sentiments may have been dampened by apprehensions regarding the company's growth outlook.
• Favorable results from Zenas BioPharma's Phase 3 trial and the thriving Hair Loss Treatment Market could have drawn investor attention away from Bristol Myers Squibb, impacting its stock trajectory.
• The optimistic forecast for the pharmaceutical sector, evidenced by growth prospects in the aminoglycosides market, might have steered investor focus elsewhere from Bristol Myers Squibb, contributing to the downward movement in its stock.

14.10.2025 - BMY Stock was down 5.5%

• Despite strong performance in the third quarter, Bristol Myers Squibb experienced a bearish movement, possibly due to profit-taking by investors after a recent 7.2% increase in share price.
• Jim Cramer's decision to back off on Bristol-Myers might have influenced investor sentiment, leading to a sell-off in the stock.
• The market may be shifting focus towards other promising opportunities like Baidu and Alibaba, as mentioned by Jim Cramer, diverting attention away from Bristol-Myers Squibb in the short term.

06.01.2026 - BMY Stock was up 5.1%

• Despite industry challenges, Bristol Myers Squibb (BMY) saw a strong bullish movement in its stock price.
• Investor optimism towards BMY is likely driven by the company surpassing analysts' expectations for adjusted earnings and revenue in the fourth quarter.
• The positive sentiment towards BMY could also be linked to the upcoming conference call to discuss financial results, hinting at potential positive developments or strategic plans.
• This upward trend may indicate that investors are focusing on Bristol Myers Squibb's resilience and ability to navigate industry challenges, rather than broader market uncertainties impacting other pharmaceutical companies.

30.09.2025 - BMY Stock was up 5.0%

• Investors are optimistic about BMY's upcoming Q3 earnings, expecting a boost from the rising demand for new therapies like Opdivo and Camzyos.
• The market movement reflects confidence in BMY's ability to navigate through declines in legacy-drug sales by focusing on its newer, more promising treatments.
• The bullish trend suggests that investors may be considering buying or holding BMY stock in anticipation of positive earnings results driven by the success of its innovative therapies.

30.09.2025 - BMY Stock was up 5.0%

• BMY saw a positive uptrend after surpassing Q3 earnings and sales expectations, boosted by the success of key drugs including Opdivo, Reblozyl, and Breyanzi.
• The decision to increase its 2025 sales forecast despite decreases in older drugs demonstrates confidence in its newer treatments and overall growth strategy.
• Market sentiment is favorable towards BMY's performance, especially as the growing demand for cutting-edge medications like Opdivo and Camzyos offsets declines in older products.

03.09.2025 - BMY Stock was down 5.0%

• BMY stock price dropped by 3.58% in the current session, continuing its downward trend over the past month and year.
• The Price Over Earnings overview indicates a decline in the stock's performance, possibly raising concerns among long-term shareholders.
• The bearish movement could be attributed to various factors such as disappointing earnings reports, regulatory setbacks, or broader market conditions impacting the pharmaceutical sector.

06.00.2026 - BMY Stock was up 5.1%

• A recent collaboration between Gilead and OncoNano Medicine utilizing OncoNano's drug delivery platform may have attracted investor interest in the pharmaceutical sector, benefiting companies like Bristol Myers Squibb.
• Robeco Institutional Asset Management B.V. raised its stake in BMY by 6.4% during the 3rd quarter, indicating a growing confidence in the company's future prospects, potentially influencing the bullish movement.
• Despite some reduction in BMY position by D.A. Davidson & CO., the overall positive sentiment towards the company, especially post exceeding earnings estimates and offering strong guidance, likely overshadowed this sell-off.
• The comparison between Zenas Biopharma's obexelimab and Amgen's Uplizna in the Phase 3 trial may have highlighted Bristol Myers Squibb's competitive edge or potential in the pharmaceutical market, fueling investor optimism and driving the stock price upwards.